Amoy Diagnostics Co Ltd Asset Resilience Ratio

Latest as of June 2026: 7.85%

Amoy Diagnostics Co Ltd asset resilience ratio. Amoy Diagnostics Co Ltd (300685) has an Asset Resilience Ratio of 7.85% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Amoy Diagnostics Co Ltd carry for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥173.83 Million
≈ $25.44 Million USD Cash + Short-term Investments

Total Assets

CN¥2.21 Billion
≈ $324.08 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Amoy Diagnostics Co Ltd (2018–2025)

Asset resilience ratio of Amoy Diagnostics Co Ltd from 2018 to 2025. This chart shows how Amoy Diagnostics Co Ltd's Asset Resilience Ratio has changed over time. See 300685 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down Amoy Diagnostics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Amoy Diagnostics Co Ltd's balance sheet.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥173.83 Million 7.85%
Total Liquid Assets CN¥173.83 Million 7.85%

Asset Resilience Insights

  • Limited Liquidity: Amoy Diagnostics Co Ltd maintains only 7.85% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Amoy Diagnostics Co Ltd Industry Peers by Asset Resilience Ratio

Compare Amoy Diagnostics Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Voxel S.A.
WAR:VOX
Diagnostics & Research 0.32%
Leveljump Healthcare Corp
V:JUMP
Diagnostics & Research 32.45%
Prodia Widyahusada Tbk PT
JK:PRDA
Diagnostics & Research 7.82%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Healius Ltd
AU:HLS
Diagnostics & Research 0.06%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%

Amoy Diagnostics Co Ltd Asset Resilience Ratio by Year (2018–2025)

Amoy Diagnostics Co Ltd asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Amoy Diagnostics Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 11.75% CN¥275.96 Million
≈ $40.38 Million
CN¥2.35 Billion
≈ $343.53 Million
-5.29pp
2024-12-31 17.04% CN¥351.89 Million
≈ $51.49 Million
CN¥2.06 Billion
≈ $302.15 Million
-7.20pp
2023-12-31 24.25% CN¥469.12 Million
≈ $68.65 Million
CN¥1.93 Billion
≈ $283.13 Million
+8.54pp
2022-12-31 15.71% CN¥259.30 Million
≈ $37.94 Million
CN¥1.65 Billion
≈ $241.58 Million
-5.08pp
2021-12-31 20.78% CN¥315.85 Million
≈ $46.22 Million
CN¥1.52 Billion
≈ $222.41 Million
-2.80pp
2020-12-31 23.58% CN¥304.86 Million
≈ $44.61 Million
CN¥1.29 Billion
≈ $189.19 Million
+20.71pp
2019-12-31 2.87% CN¥30.06 Million
≈ $4.40 Million
CN¥1.05 Billion
≈ $153.18 Million
+2.86pp
2018-12-31 0.01% CN¥90.36K
≈ $13.22K
CN¥818.75 Million
≈ $119.81 Million
--
pp = percentage points

About Amoy Diagnostics Co Ltd

SHE:300685 China Diagnostics & Research
Market Cap
$1.09 Billion
CN¥7.45 Billion CNY
Market Cap Rank
#8199 Global
#1805 in China
Share Price
CN¥19.09
Change (1 day)
-3.54%
52-Week Range
CN¥16.18 - CN¥23.82
All Time High
CN¥57.70
About

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive … Read more